ABSTRACT
I. The decision to use intravenously administered immunoglobulin (TVlg) in a variety of autoimmune diseases, including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), dermatomyositis/polymyositis (DM/PM), vasculitis, neurological diseases such as Guillain-Barre syndrome (GBS), multiple sclerosis, amyotrophic lateral sclerosis, and myasthenia gravis, and hematological diseases such as autoimmune hemolytic anemia was largely based on its successful empirical use in idiopathic thrombocytopenic purpura (TTP). Randomized controlled trials (RCTs) have subsequently confirmed the efficacy ofIVIg therapy compared to aspirin in Kawasaki disease (KD) ( J ,2), to corticosteroids in ITP (3), to placebo in DM (4), and to plasmapheresis in OBS (5).
